International Clinical Trials Registry Platform (ICTRP)

The Netherlands National Trial Register (NTR)

Registry Profile



  • Funding Agency: Netherlands Organisation for Health Research and Development (ZonMw; main funding agency). Additional funding from the Health Council (Gezondheidsraad); Dutch Cancer Society (KWF); Dutch College of General Practitioners (NHG); Aids Fonds

  • Managing Agency: Dutch Cochrane Centre (DCC)

  • Description:
    The NTR is advised by an external Advisory Board whose role is to advise on the scope, operation, accessibility, sustainability and (inter)national obligations of the NTR. The board currently consists of experts from Netherlands Organization for Health Research and Development (ZonMw), the Dutch Institute for Healthcare Improvement (CBO), the Dutch Federation of University Medical Centers (NFU), the Dutch association of Research-oriented pharmaceutical industry (NEFARMA), and the Dutch Cochrane Centre. Additionally, an editor of the Nederlands Tijdschrift voor Geneeskunde (ICMJE member) and the rector magnificus of VU Medical Center - who is also member of Central Committee on Research inv. Human Subjects (CCMO)- are both consultants for the NTR.

Registry Criteria

  • Does the Registry accept prospective registration of interventional clinical trials submitted by Responsible Registrants?

  • Does the Registry have documented Standard Operating Procedures (SOPs)?

    • Are mechanisms in place to ensure compliance with these SOPs? (eg staff training)

    • Description of the compliance mechanisms:
      Information currently unavailable

  • Does the Registry agree to participate in the development of Guidelines for Clinical Trial Registries?

  • Can the Registry collect and publicly display the WHO Trial Registration Data Set (TRDS)?
    Yes, Click here to view the details.

    • Languages in which the registered information is displayed:

    • What quality control measures does your Registry have in place to make sure that all 20 items in the WHO TRDS are as complete and accurate as possible?
      Before a registrant can register their trial, they have to apply for an login code. They receive this code by email, so we always have a contact detail. This email address is usually job specific. Sometimes login codes are applied with a personal address (for example yahoo or hotmail), in this cases we (double) check if the contact details are properly given in the registration form. Additionally, we randomly check if the researchers actually work at the institute they applied (for example on sites of their hospital or by using Google).

      We do not accept incomplete submissions, we only make a temporarily exceptions. For example, when only a few items are missed or when unclear information is given, we make the trial information openly accessible before asking for further information. We never register a trial lacking (crucial) information, when additional information is not given after 3 warnings (usually in a period of three months) the trial is deleted from our register. Information on the trial website, acronym and hypothesis can be left incomplete.

      We identify incomplete of non-informative entries by manual checking the data by trial administrators. Additionally, we ask for updates of the information. Many registrants apply updated information on their own initiative (for example: please change planned study into recruiting patients). Other researchers receive an email alert once a year.

  • Does the Registry flag trials that do not provide the complete WHO Trial Registration Data Set at the time of initial registration?
    Information currently unavailable

  • Does the Registry agree to submit the WHO Trial Registration Data Set, in English, to the Central Repository?

  • Does the Registry agree to keep registered information up-to-date?

  • Does the Registry agree to maintain a publicly accessible audit trail so changes made to the WHO Trial Registration Data Set can be tracked?

  • Does the Registry agree to never to remove a trial once it has been registered?

  • Does the Registry publicly disclose ownership, governance structure and not/for-profit status?

  • Does the Registry agree to inform the WHO ICTRP Secretariat of changes that may be relevant to its status as a Collaborating Registry in the Registry Network?

  • Is the Registry searchable over the Internet at no charge?

  • Is the Registry open to all prospective registrants?

  • From which countries will the Registry accept trials for registration?
    All Countries